Hubei Clinical Research Center

Hubei Clinical Research Center of Tumor Immunotherapy

Name: Hubei Clinical Research Center of Tumor Immunotherapy

Person in Charge: Wang Hongbo

Brief Introduction: Research Directions: Design and carry out clinical trials of tumor immunotherapy, conduct in-depth molecular research on tumor immune microenvironment, explore new targets and new mechanisms of tumor immunotherapy, clarify the anti-tumor effect of T cells, NK cells and other immune cells, and carry out the research and development of drugs and tumor vaccines related to tumor immunotherapy.


Achievements: The team members of the center have won a second prize of National Science and Technology Progress Award, a first prize and two second prizes of Hubei Province Science and Technology Progress Award. They presided over and took part in more than 20 clinical trials related to tumor immunotherapy; participated in the compilation of more than 10 guidelines and consensuses, obtained more than 20 invention and utility model patents, and published more than 400 papers, including more than 300 SCI papers and more than 20 papers in such high-level journals as Science Advances, Nature Communications, Nucleic Acids Research, ACS Nano, etc.